Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziritaxestat (GLPG1690) in Systemic Sclerosis
NCT03798366Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing GLPG1690 600 mg with Placebo (2 arms). Primary endpoint: Change From Baseline in modified Rodnan Skin Score at 24 weeks. Started Jan 2019; status: completed.
02
Drugs
ziritaxestat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT03798366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798366.